{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:21:33Z","timestamp":1778718093025,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":455,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1111\/jth.15187","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T23:28:51Z","timestamp":1608247731000},"page":"32-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"S1","title":["Application of a hemophilia mortality framework to the Emicizumab Global Safety Database"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7423-9864","authenticated-orcid":false,"given":"Flora","family":"Peyvandi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johnny N.","family":"Mahlangu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2558-2089","authenticated-orcid":false,"given":"Steven W.","family":"Pipe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles R.M.","family":"Hay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn F.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Kuebler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Kruse\u2010Jarres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Midori","family":"Shima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/jth.15187_bb0010","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1080\/03007995.2019.1649378","article-title":"Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta\u2010analysis and sub\u2010group analyses of the intra\u2010patient comparison of the HAVEN 3 trial","volume":"35","author":"Reyes","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/jth.15187_bb0015","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1111\/hae.13822","article-title":"Safety and efficacy of emicizumab and other novel agents in newborns and infants","volume":"25","author":"Pierce","year":"2019","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15187_bb0020","unstructured":"Food and Drug Administration. HEMLIBRA\u00ae (emicizumab\u2010kxwh) injection for subcutaneous use, prescribing information. Initial U.S. approval: 2017. 2018; https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761083s000lbl.pdf. Accessed April 28, 2020."},{"key":"10.1111\/jth.15187_bb0025","unstructured":"European Medicines Agency. HEMLIBRA\u00ae solution for injection: emicizumab piIEa. Initial EU approval: 2018. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/hemlibra\u2010epar\u2010product\u2010information_en.pdf. Accessed April 28, 2020."},{"key":"10.1111\/jth.15187_bb0030","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"key":"10.1111\/jth.15187_bb0035","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII\u2010mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"Shima","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15187_bb0040","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15187_bb0045","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open\u2010label, phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"key":"10.1111\/jth.15187_bb0050","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15187_bb0055","doi-asserted-by":"crossref","first-page":"E295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia (HAVEN 4): a multicentre, open\u2010label, non\u2010randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1111\/jth.15187_bb0060","article-title":"Long\u2010term outcomes with emicizumab prophylaxis for hemophilia A with\/without FVIII inhibitors from the HAVEN 1\u20134 studies","author":"Callaghan","year":"2020","journal-title":"Blood"},{"key":"10.1111\/jth.15187_bb0065","first-page":"116","article-title":"A single\u2010arm, multicentre, open\u2010label, phase III clinical trial to evaluate the safety and tolerability of prophylactic emicizumab in persons with haemophilia A (PwHA) with FVIII inhibitors (STASEY): interim analysis results","volume":"3","author":"Jim\u00e9nez\u2010Yuste","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1111\/jth.15187_bb0070","unstructured":"ATHN 7: Hemophilia Natural History Study (ATHN 7). 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03619863. Accessed August 20, 2020."},{"issue":"Suppl. 1","key":"10.1111\/jth.15187_bb0075","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/jth.15189","article-title":"Mortality in congenital hemophilia A \u2010 a systematic literature review","volume":"19","author":"Hay","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15187_bb0080","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/ofid\/ofaa044","article-title":"Life expectancy of insured people with and without hepatitis C virus infection","volume":"7","author":"Marcus","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1111\/jth.15187_bb0085","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(08)61113-7","article-title":"Life expectancy of individuals on combination antiretroviral therapy in high\u2010income countries: a collaborative analysis of 14 cohort studies","volume":"372","year":"2008","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1111\/jth.15187_bb0090","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/jth.15186","article-title":"Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database","volume":"19","author":"Pipe","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15187_bb0095","unstructured":"U.S. Department of Health & Human Services. The HIPAA Privacy Rule. 2002. https:\/\/www.hhs.gov\/hipaa\/for\u2010professionals\/privacy\/laws\u2010regulations\/index.html. Accessed August 12, 2020."},{"key":"10.1111\/jth.15187_bb0100","unstructured":"Centers for Disease Control and Prevention. Leading causes of death. 2020. https:\/\/www.cdc.gov\/nchs\/fastats\/leading\u2010causes\u2010of\u2010death.htm. Accessed August 19, 2020."},{"key":"10.1111\/jth.15187_bb0105","unstructured":"World Health Organization. The top 10 causes of death. 2020. https:\/\/www.who.int\/news\u2010room\/fact\u2010sheets\/detail\/the\u2010top\u201010\u2010causes\u2010of\u2010death. Accessed August 19, 2020."},{"key":"10.1111\/jth.15187_bb0110","first-page":"1","article-title":"Case report of a fatal rectal haemorrhage in a person with severe haemophilia A receiving emicizumab and high\u2010dose bypassing agents in the HAVEN 1 study","volume":"00","author":"Khoo","year":"2020","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15187_bb0115","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/hepr.12393","article-title":"Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon\u2010based antiviral therapy","volume":"45","author":"Hiramatsu","year":"2015","journal-title":"Hepatol Res"},{"key":"10.1111\/jth.15187_bb0120","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/jth.12990","article-title":"Inhibitor development and mortality in non\u2010severe hemophilia A","volume":"13","author":"Eckhardt","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15187_bb0125","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1111\/hae.13730","article-title":"Mortality of patients with haemophilia in Brazil: first report","volume":"25","author":"Jardim","year":"2019","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15187_bb0130","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ajh.23957","article-title":"United States Hemophilia Treatment Center Network. Impact of inhibitors on hemophilia A mortality in the United States","volume":"90","author":"Walsh","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1111\/jth.15187_bb0135","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.1111\/hae.12475","article-title":"Life expectancy of Korean haemophiliacs, 1991\u20132012","volume":"20","author":"Yoo","year":"2014","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15187_bb0140","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1365-2141.2010.08469.x","article-title":"Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States","volume":"152","author":"Witmer","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.15187_bb0145","first-page":"e38","article-title":"Heart disease and stroke statistics\u20132016 update. A report from the American Heart Association","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"key":"10.1111\/jth.15187_bb0150","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1182\/blood.2019004334","article-title":"A hemophilia A mouse model for the in vivo assessment of emicizumab function","volume":"136","author":"Ferri\u00e8re","year":"2020","journal-title":"Blood"},{"key":"10.1111\/jth.15187_bb0155","article-title":"Pharmacokinetics and pharmacodynamics of emicizumab in persons with hemophilia A with factor VIII inhibitors: HAVEN 1 Study","author":"Schmitt","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.15187_bb0160","doi-asserted-by":"crossref","first-page":"307","DOI":"10.5482\/20170004","article-title":"Thromboembolic risks of non\u2010factor replacement therapies in hemophilia","volume":"37","author":"Tiede","year":"2017","journal-title":"Hamostaseologie"},{"key":"10.1111\/jth.15187_bb0165","unstructured":"Novo Nordisk. Press release: Novo Nordisk resumes the phase 3 clinical trials investigating concizumab (anti\u2010TFPI mAB) in haemophilia A and B with or without inhibitors. 2020. https:\/\/ml\u2010eu.globenewswire.com\/Resource\/Download\/32302d78\u2010439f\u20104a97\u2010a655\u20103f7b96e2cc76. Accessed November 30, 2020."},{"key":"10.1111\/jth.15187_bb0170","first-page":"95","article-title":"Summary of thromboembolic (TE) or thrombotic microangiopathy (TMA) events in persons taking emicizumab","volume":"26","author":"Lee","year":"2020","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15187_bb0175","unstructured":"Food and Drug Administration. NovoSeven highlights of prescribing information. [Last updated: July 2014]. 1999. https:\/\/www.fda.gov\/media\/70442\/download. Accessed August 12, 2020."},{"key":"10.1111\/jth.15187_bb0180","unstructured":"Food and Drug Administration. FEIBA highlights of prescribing information. [Last updated: November 2013]. 1986. https:\/\/www.fda.gov\/media\/78852\/download. Accessed August 12, 2020."},{"key":"10.1111\/jth.15187_bb0185","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1111\/j.1538-7836.2006.02213.x","article-title":"The tragic history of AIDS in the hemophilia population, 1982\u20131984","volume":"4","author":"Evatt","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15187_bb0190","first-page":"229","article-title":"Adverse effects of antiretroviral therapy for HIV infection","volume":"170","author":"Montessori","year":"2004","journal-title":"CMAJ"},{"key":"10.1111\/jth.15187_bb0195","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/00002030-200402200-00020","article-title":"The impact of HIV on mortality rates in the complete UK haemophilia population","volume":"18","year":"2004","journal-title":"AIDS"},{"issue":"Pt 2","key":"10.1111\/jth.15187_bb0200","first-page":"912","article-title":"Life time expectancy of hemophilia patients infected with HIV\u20101 with the risk of hepatocellular carcinoma after HCV infection","volume":"8","author":"Tatsunami","year":"1995","journal-title":"MedInfo"},{"key":"10.1111\/jth.15187_bb0205","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1665-2681(19)30977-9","article-title":"Survival of hepatitis C\u2010infected haemophilia patients is predicted by presence of cirrhosis but not by anti\u2010viral treatment","volume":"13","author":"Maor","year":"2014","journal-title":"Ann Hepatol"},{"key":"10.1111\/jth.15187_bb0210","doi-asserted-by":"crossref","first-page":"e494","DOI":"10.1111\/hae.13020","article-title":"Long\u2010term liver\u2010related morbidity and mortality related to chronic hepatitis C virus infection in Swedish patients with inherited bleeding disorders","volume":"22","author":"Holmstr\u00f6m","year":"2016","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15187_bb0215","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/sim.4780100409","article-title":"Channeling bias in the interpretation of drug effects","volume":"10","author":"Petri","year":"1991","journal-title":"Stat Med"},{"key":"10.1111\/jth.15187_bb0220","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/acr.23303","article-title":"Treatment of rheumatoid arthritis with anti\u2010atumor necrosis factor or tocilizumab therapy as first biologic agent in a global comparative observational study","volume":"69","author":"Choy","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1111\/jth.15187_bb0225","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","article-title":"The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty\u2010two drugs approved from 2006 to 2010","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf"},{"key":"10.1111\/jth.15187_bb0230","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/hae.13618","article-title":"The effect of emicizumab prophylaxis on health\u2010related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study","volume":"25","author":"Oldenburg","year":"2019","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15187_bb0235","series-title":"Registries for Evaluating Patient Outcomes: A User's Guide [Internet]","author":"Gliklich","year":"2014"},{"key":"10.1111\/jth.15187_bb0240","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1111\/jth.13762","article-title":"Minimal dataset for post\u2010registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH","volume":"15","author":"Peyvandi","year":"2017","journal-title":"J Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15187","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.15187","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622021250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622021250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15187","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:28:42Z","timestamp":1761535722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622021250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":47,"alternative-id":["S1538783622021250"],"URL":"https:\/\/doi.org\/10.1111\/jth.15187","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Application of a hemophilia mortality framework to the Emicizumab Global Safety Database","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.15187","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 The Authors. Journal of Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}]}}